These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 25979349)

  • 1. Denosumab for low bone mass in hemodialysis patients: a noncontrolled trial.
    Hiramatsu R; Ubara Y; Sawa N; Hoshino J; Hasegawa E; Kawada M; Imafuku A; Sumida K; Mise K; Hayami N; Suwabe T; Takaichi K
    Am J Kidney Dis; 2015 Jul; 66(1):175-7. PubMed ID: 25979349
    [No Abstract]   [Full Text] [Related]  

  • 2. Osteopenia during long-term haemodialysis: response to vitamin D3 analogues.
    Muirhead N; Adami S; Fraser RA; Catto GR; Edward N; O'Riordan JL
    Proc Eur Dial Transplant Assoc; 1981; 18():567-72. PubMed ID: 6895786
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of Denosumab and Calcitriol on Severe Secondary Hyperparathyroidism in Dialysis Patients With Low Bone Mass.
    Chen CL; Chen NC; Liang HL; Hsu CY; Chou KJ; Fang HC; Lee PT
    J Clin Endocrinol Metab; 2015 Jul; 100(7):2784-92. PubMed ID: 25955225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The effects of estrogen on renal osteodystrophy in the female patients undergoing maintenance hemodialysis].
    Akino H; Saito A; Maeda S; Kitajima W; Okano M; Isomatsu Y; Muranaka K; Kanimoto Y; Shimizu Y; Kawada Y
    Nihon Jinzo Gakkai Shi; 1986 Aug; 28(8):1129-36. PubMed ID: 3807045
    [No Abstract]   [Full Text] [Related]  

  • 5. Identification of the risk factors associated with hypocalcemia induced by denosumab.
    Okada N; Kawazoe K; Teraoka K; Kujime T; Abe M; Shinohara Y; Minakuchi K
    Biol Pharm Bull; 2013; 36(10):1622-6. PubMed ID: 23934346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New agents for the treatment of renal osteodystrophy.
    Ledger S
    CANNT J; 2004; 14(4):16-21; quiz 21-2. PubMed ID: 15673151
    [No Abstract]   [Full Text] [Related]  

  • 7. Investigational drug slows bone erosion.
    Hampton T
    JAMA; 2007 Dec; 298(24):2856. PubMed ID: 18159051
    [No Abstract]   [Full Text] [Related]  

  • 8. Severe hypocalcemia following denosumab injection in a hemodialysis patient.
    McCormick BB; Davis J; Burns KD
    Am J Kidney Dis; 2012 Oct; 60(4):626-8. PubMed ID: 22854051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Kidney and bone update : the 5-year history and future of CKD-MBD. Bone fragility in the aged hemodialysis patients].
    Imanishi Y
    Clin Calcium; 2012 Jul; 22(7):1025-33. PubMed ID: 22750935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of cinacalcet in management of mineral bone disorder in chronic kidney disease (control of calcium, phosphorus and parathyroid hormone).
    Tahara H
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S27-33. PubMed ID: 19032524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphophonates in CKD patients with low bone mineral density.
    Liu WC; Yen JF; Lang CL; Yan MT; Lu KC
    ScientificWorldJournal; 2013; 2013():837573. PubMed ID: 24501586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Denosumab associated with bone density increase and clinical improvement in a long-term hemodialysis patient. Case report and review of the literature.
    Dusilova Sulkova S; Horacek J; Safranek R; Gorun P; Viklicky O; Palicka V
    Acta Medica (Hradec Kralove); 2014; 57(1):30-3. PubMed ID: 25006661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Denosumab-Associated Severe Hypocalcemia in Dialysis-Dependent Patients.
    Schoenmakers I; Fraser WD
    JAMA; 2024 Jun; 331(21):1864-1865. PubMed ID: 38717748
    [No Abstract]   [Full Text] [Related]  

  • 14. New anti-resorptives and antibody mediated anti-resorptive therapy.
    Farrier AJ; Sanchez Franco LC; Shoaib A; Gulati V; Johnson N; Uzoigwe CE; Choudhury MZ
    Bone Joint J; 2016 Feb; 98-B(2):160-5. PubMed ID: 26850419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denosumab anf cronic kidney disease: Severe life-threatening hypocalcemia.
    Monge Rafael P; Martin de Francisco ÁL; Fernández-Fresnedo G
    Nefrologia (Engl Ed); 2018; 38(1):97-98. PubMed ID: 29325673
    [No Abstract]   [Full Text] [Related]  

  • 16. [Effects of 1 alpha-(OH)D3 on renal osteodystrophy--a 5-year retrospective evaluation].
    Kakuhara T; Mizoguchi M; Itoh M; Nagasawa M; Mori T; Ohtsuka K; Kubota M; Minatoguchi T; Ohara K; Yoshida M; Koide H; Ohno J
    Nihon Jinzo Gakkai Shi; 1982 Jun; 24(6):693-704. PubMed ID: 7176180
    [No Abstract]   [Full Text] [Related]  

  • 17. An open-label, prospective pilot clinical study of denosumab for severe hyperparathyroidism in patients with low bone mass undergoing dialysis.
    Chen CL; Chen NC; Hsu CY; Chou KJ; Lee PT; Fang HC; Renn JH
    J Clin Endocrinol Metab; 2014 Jul; 99(7):2426-32. PubMed ID: 24670088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of reduced bone density with ibandronate in dialysis patients.
    Bergner R; Henrich D; Hoffmann M; Schmidt-Gayk H; Lenz T; Upperkamp M
    J Nephrol; 2008; 21(4):510-6. PubMed ID: 18651540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Variations in serum levels of phosphorus (iP), calcium (Ca), calcitonin (iCT) and parathormone (iPTH) in patients under periodic hemodialysis. Effects of exogenous calcitonin therapy].
    Bucciante G; Bernardi A; Biasia F; Milan G; Donato D
    Minerva Med; 1985 Mar; 76(9-10):415-7. PubMed ID: 3982698
    [No Abstract]   [Full Text] [Related]  

  • 20. Severe hypocalcemia following denosumab injection in patient with chronic kidney disease.
    Monge Rafael P; Arias M; Fernández-Fresnedo G
    Nefrologia; 2016; 36(4):446-8. PubMed ID: 27012438
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.